The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...

Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast ...

AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been ...

There has been another twist in the road for the ongoing legal battle between Seagen and Daiichi Sankyo over patent rights for antibody-drug conjugate (ADC) Enhertu. The US Patent and Trademark ...

Affirm Holdings, Inc. , the payment network that empowers consumers and helps merchants drive growth, today announced that Rob O'Hare, CFO of Affirm, will participate in a fireside chat to answer a ...

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...

Dynaprice.com, Inc. today announced definitive agreement and completion of all closing conditions to merge with Dinamo Acquisition Corporation. Through this merger, control of the company passes to a ...

Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.

TOKYO, January 31, 2025--Daiichi Sankyo Company, Ltd (TSE ... The FDA approves AstraZeneca's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer in the United States.